Recent developments in bioinformatics analyses of influenza a virus surface glycoproteins and their biological relevance

Current Bioinformatics

Volumn 6, Issue 4, 2011, Pages 415-426

  Hashem, Anwar M ^a,b   Doyle, Tracey M ^a   van Domselaar, Gary ^c   Farnsworth, Aaron ^a   Li, Changgui ^d   Wang, Junzhi ^d   He, Runtao ^c   Li, Xuguang ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

^b Aziz University   (Saudi Arabia)

^c PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^d NATIONAL INSTITUTE FOR THE CONTROL OF PHARMACEUTICAL AND BIOLOGICAL PRODUCTS   (China)

Author keywords

Bioinformatics; Conserved sequences; Cross neutralizing antibodies; Hemagglutinin; Influenza a virus; Neuraminidase; Universal vaccine

Indexed keywords

EPITOPES; GLYCOPROTEINS; MACROINVERTEBRATES;

ANTIVIRALS; BIOINFORMATICS ANALYSIS; CONSERVED SEQUENCE; CROSS-NEUTRALIZING ANTIBODY; HEMAGGLUTININ; INFLUENZA A VIRUS; NEURAMINIDASE; NEUTRALIZING ANTIBODIES; SURFACE GLYCOPROTEINS; UNIVERSAL VACCINE;

VACCINES;

ANTIVIRUS AGENT; HEMAGGLUTININ; INFLUENZA VACCINE; MICRORNA; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; OSELTAMIVIR; SIALIDASE; TRIPEPTIDE; VIRUS GLYCOPROTEIN; VIRUS VACCINE; ZANAMIVIR;

ANTIVIRAL RESISTANCE; ARTICLE; BIOINFORMATICS; CROSS REACTION; CYTOTOXIC T LYMPHOCYTE; DRUG TARGETING; GENETIC ANALYSIS; GENETIC ASSOCIATION; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNITY; INFLUENZA; INFLUENZA VIRUS A; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS A H5N1; NONHUMAN; POTENCY DISORDER; PRIORITY JOURNAL; VIRUS GENOME;

ANIMALIA; INFLUENZA A VIRUS; SUIDAE;

EID: 81155124042     PISSN: 15748936     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489311798073007     Document Type: Article

References (155)

1. Smith NM, Bresee JS, Shay DK, Uyeki TM, Cox NJ, Strikas RA. Prevention and Control of Influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006; 55: 1-42.
2. Zambon MC. Epidemiology and pathogenesis of influenza. J Antimicrob Chemother 1999; 44: 3-9.
3. Hannoun C, Megas F, Piercy J. Immunogenicity and protective efficacy of influenza vaccination. Virus Res 2004; 103: 133-8.
4. Simonsen L, Taylor RJ, Viboud C, Miller MA, Jackson LA. Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. Lancet Infect Dis 2007; 7: 658-66.
5. Poland GA, Rottinghaus ST, Jacobson RM. Influenza vaccines: a review and rationale for use in developed and underdeveloped countries. Vaccine 2001; 19: 2216-20.
6. Du L, Zhou Y, Jiang S. Research and development of universal influenza vaccines. Microbes Infect 2010; 12: 280-6.
7. Kilbourne ED. Influenza immunity: new insights from old studies. J Infect Dis 2006; 193: 7-8.
8. Stevens J, Blixt O, Tumpey TM, Taubenberger JK, Paulson JC, Wilson IA. Structure and receptor specificity of the hemagglutinin from an H5N1 influenza virus. Science 2006; 312: 404-10.
9. Nabel GJ, Fauci AS. Induction of unnatural immunity: prospects for a broadly protective universal influenza vaccine. Nat Med 2010; 16: 1389-91.
10. Sui J, Hwang WC, Perez S, et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 2009; 16: 265-73.
11. Capua I, Alexander DJ. Human health implications of avian influenza viruses and paramyxoviruses. Eur J Clin Microbiol Infect Dis 2004; 23: 1-6.
12. Palese P. Influenza: old and new threats. Nat Med 2004; 10: S82-7.
13. Steinhauer DA, Skehel JJ. Genetics of influenza viruses. Annu Rev Genet 2002; 36: 305-32.
14. Puthavathana P, Auewarakul P, Charoenying PC, et al. Molecular characterization of the complete genome of human influenza H5N1 virus isolates from Thailand. J Gen Virol 2005; 86: 423-33.
15. Skehel JJ, Wiley DC. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu Rev Biochem 2000; 69: 531-69.
16. Cross KJ, Langley WA, Russell RJ, Skehel JJ, Steinhauer DA. Composition and functions of the influenza fusion peptide. Protein Pept Lett 2009; 16: 766-78.
17. Wiley DC, Skehel JJ. The structure and function of the hemagglutinin membrane glycoprotein of influenza virus. Annu Rev Biochem 1987; 56: 365-394.
18. Chen J, Wharton SA, Weissenhorn W, et al. A soluble domain of the membrane-anchoring chain of influenza virus hemagglutinin (HA2) folds in Escherichia coli into the low-pH-induced conformation. Proc Natl Acad Sci USA 1995; 92: 12205-9.
19. Gething MJ, Doms RW, York D, White J. Studies on the mechanism of membrane fusion: site-specific mutagenesis of the hemagglutinin of influenza virus. J Cell Biol 1986; 102: 11-23.
20. Varghese JN, Webster RG, Laver WG, Colman PM. Structure of an escape mutant of glycoprotein N2 neuraminidase of influenza virus A/Tokyo/3/67 at 3 A. J Mol Biol 1988; 200: 201-3.
21. Varghese JN, Laver WG, Colman PM. Structure of the influenzavirus glycoprotein antigen neuraminidase at 2.9 A resolution. Nature 1983; 303: 35-40.
22. Colman PM. Influenza virus neuraminidase: structure, antibodies, and inhibitors. Protein Sci 1994; 3: 1687-96.
23. Air GM, Laver WG. The neuraminidase of influenza virus. Proteins 1989; 6: 341-56.
24. Palese P, Tobita K, Ueda M, Compans RW. Characterization of temperature sensitive nfluenza virus mutants defective in neuraminidase. Virology 1974; 61: 397-410.
25. Griffin JA, Basak S, Compans RW. Effects of hexose starvation and the role of sialic acid in influenza virus release. Virology 1983; 125: 324-34.
26. Liu C, Eichelberger MC, Compans RW, Air GM. Influenza type A virus neuraminidase does not play a role in viral entry, replication, assembly, or budding. J Virol 1995; 69: 1099-106.
27. Hashem AM, Flaman AS, Farnsworth A, et al. Aurintricarboxylic acid is a potent inhibitor of influenza A and B virus neuraminidases. PLoS One 2009; 4: e8350.
28. Colman PM, Varghese JN, Laver WG. Structure of the catalytic and antigenic sites in influenza virus neuraminidase. Nature 1983; 303: 41-4.
29. Klenk HD, Rott R. The molecular biology of influenza virus pathogenicity. Adv Virus Res 1988; 34: 247-81.
30. Ohuchi M, Asaoka N, Sakai T, Ohuchi R. Roles of neuraminidase in the initial stage of influenza virus infection. Microbes Infect 2006; 8: 1287-93.
31. Su B, Wurtzer S, Rameix-Welti MA, et al. Enhancement of the influenza A hemagglutinin (HA)-mediated cell-cell fusion and virus entry by the viral neuraminidase (NA). PLoS One 2009; 4: e8495.
32. Gerhard W, Mozdzanowska K, Zharikova D. Prospects for universal influenza virus vaccine. Emerg Infect Dis 2006; 12: 569-74.
33. Epstein SL. Prior H1N1 influenza infection and susceptibility of Cleveland Family Study participants during the H2N2 pandemic of 1957: an experiment of nature. J Infect Dis 2006; 193: 49-53.
34. Prabhu N, Prabakaran M, Ho HT, et al. Monoclonal antibodies against the fusion peptide of hemagglutinin protect mice from lethal influenza A virus H5N1 infection. J Virol 2009; 83: 2553-62.
35. Hashem AM, Van Domselaar G, Li C, et al. Universal antibodies against the highly conserved influenza fusion peptide cross-neutralize several subtypes of influenza A virus. Biochem Biophys Res Commun 2010; 403: 247-51.
36. Huber VC, Peltola V, Iverson AR, McCullers JA. Contribution of vaccine-induced immunity toward either the HA or the NA component of influenza viruses limits secondary bacterial complications. J Virol 2010; 84: 4105-8.
37. Marasco WA, Sui J. The growth and potential of human antiviral monoclonal antibody therapeutics. Nat Biotechnol 2007; 25: 1421-34.
38. Stanekova Z, Vareckova E. Conserved epitopes of influenza A virus inducing protective immunity and their prospects for universal vaccine development. Virol J 2010; 7(351).
39. Ludwig S, Planz O, Pleschka S, Wolff T. Influenza-virus-induced signaling cascades: targets for antiviral therapy? Trends Mol Med 2003; 9: 46-52.
40. Ong AK, Hayden FG., John F. Enders lecture 2006: antivirals for influenza. J Infect Dis 2007; 196: 181-90.
41. Regoes RR, Bonhoeffer S. Emergence of drug-resistant influenza virus: population dynamical considerations. Science 2006; 312: 389-91.
42. Fiore AE, Shay DK, Broder K, et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Recomm Rep 2008; 57: 1-60.
43. Deyde VM, Okomo-Adhiambo M, Sheu TG, et al. Pyrosequencing as a tool to detect molecular markers of resistance to neuraminidase inhibitors in seasonal influenza A viruses. Antiviral Res 2009; 81: 16-24.
44. Palese P. Making better influenza virus vaccines? Emerg Infect Dis 2006; 12: 61-5.
45. Bergen R, Black S, Shinefield H, et al. Safety of cold-adapted live attenuated influenza vaccine in a large cohort of children and adolescents. Pediatr Infect Dis J 2004; 23: 138-44.
46. Wood JM. Selection of influenza vaccine strains and developing pandemic vaccines. Vaccine 2002; 20: B40-4.
47. Carrat F, Flahault A. Influenza vaccine: the challenge of antigenic drift. Vaccine 2007; 25: 6852-62.
48. Drape RJ, Macklin MD, Barr LJ, Jones S, Haynes JR, Dean HJ. Epidermal DNA vaccine for influenza is immunogenic in humans. Vaccine 2006; 24: 4475-81.
49. Fedson DS. Pandemic influenza and the global vaccine supply. Clin Infect Dis 2003; 36: 1552-61.
50. Wood JM, Major D, Newman RW, et al. Preparation of vaccines against H5N1 influenza. Vaccine 2002; 20: S84-7.
51. Aymard M, Valette M, Lina B, Thouvenot D. Surveillance and impact of influenza in Europe. Groupe Regional d'Observation de la Grippe and European Influenza Surveillance Scheme. Vaccine 1999; 17: S30-41.
52. Klimov A, Simonsen L, Fukuda K, Cox N. Surveillance and impact of influenza in the United States. Vaccine 1999; 17: S42-6.
53. de Jong JC, Beyer WE, Palache AM, Rimmelzwaan GF, Osterhaus AD. Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly. J Med Virol 2000; 61: 94-9.
54. Yohannes K, Roche P, Hampson A, Miller M, Spencer J. Annual report of the National Influenza Surveillance Scheme, 2003. Commun Dis Intell 2004; 28: 160-8.
55. Bridges CB, Thompson WW, Meltzer MI, et al. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: A randomized controlled trial. JAMA 2000; 284: 1655-63.
56. De Filette M, Min Jou W, Birkett A, et al. Universal influenza A vaccine: optimization of M2-based constructs. Virology 2005; 337: 149-61.
57. Bao Y, Bolotov P, Dernovoy D, et al. The influenza virus resource at the national center for biotechnology information. J Virol 2008; 82: 596-601.
58. Macken C, Lu H, Goodman J, Boykin L. The value of a database in surveillance and vaccine selection. Int Congr Ser 2001; 1219: 103-6.
59. Squires B, Macken C, Garcia-Sastre A, et al. BioHealthBase: informatics support in the elucidation of influenza virus host pathogen interactions and virulence. Nucleic Acids Res 2008; 36 (Database issue): D497-503.
60. Liechti R, Gleizes A, Kuznetsov D, et al. OpenFluDB, a database for human and animal influenza virus. Database 2010; doi:10.1093/database/baq004.
61. Lu G, Rowley T, Garten R, Donis RO. FluGenome: a web tool for genotyping influenza A virus. Nucleic Acids Res 2007; 35 (Web Server issue): W275-9.
62. Wang S, Sundaram JP, Spiro D. VIGOR, an annotation program for small viral genomes. BMC Bioinformatics 2010; 11(451).
63. Steel J, Lowen AC, Wang T, et al. Influenza virus vaccine based on the conserved hemagglutinin stalk domain. MBio 2010; 1: e00018-10.
64. Rimmelzwaan GF, Fouchier RA, Osterhaus AD. Influenza virus-specific cytotoxic T lymphocytes: a correlate of protection and a basis for vaccine development. Curr Opin Biotechnol 2007; 18: 529-36.
65. Epstein SL, Kong WP, Misplon JA, et al. Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine 2005; 23: 5404-10.
66. Saha S, Yoshida S, Ohba K, et al. A fused gene of nucleoprotein (NP) and herpes simplex virus genes (VP22) induces highly protective immunity against different subtypes of influenza virus. Virology 2006; 354: 48-57.
67. Tompkins SM, Zhao ZS, Lo CY, et al. Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerg Infect Dis 2007; 13: 426-35.
68. Tamura S, Tanimoto T, Kurata T. Mechanisms of broad cross-protection provided by influenza virus infection and their application to vaccines. Jpn J Infect Dis 2005; 58: 195-207.
69. Grandea AG 3rd, Olsen OA, Cox TC, et al. Human antibodies reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses. Proc Natl Acad Sci USA 2010; 107: 12658-63.
70. Nguyen HH, van Ginkel FW, Vu HL, McGhee JR, Mestecky J. Heterosubtypic immunity to influenza A virus infection requires B cells but not CD8+ cytotoxic T lymphocytes. J Infect Dis 2001; 183: 368-76.
71. Quan FS, Compans RW, Nguyen HH, Kang SM. Induction of heterosubtypic immunity to influenza virus by intranasal immunization. J Virol 2008; 82: 1350-9.
72. Tumpey TM, Renshaw M, Clements JD, Katz JM. Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection. J Virol 2001; 75: 5141-50.
73. Takada A, Matsushita S, Ninomiya A, Kawaoka Y, Kida H. Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza A virus infection in mice. Vaccine 2003; 21: 3212-8.
74. Wei CJ, Boyington JC, McTamney PM, et al. Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science 2010; 329: 1060-4.
75. Wang TT, Tan GS, Hai R, et al. Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proc Natl Acad Sci U S A 2010; 107: 18979-84.
76. Bommakanti G, Citron MP, Hepler RW, et al. Design of an HA2-based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge. Proc Natl Acad Sci U S A 2010; 107: 13701-6.
77. Kreijtz JH, Bodewes R, van Amerongen G, et al. Primary influenza A virus infection induces cross-protective immunity against a lethal infection with a heterosubtypic virus strain in mice. Vaccine 2007; 25: 612-20.
78. Styk B, Russ G, Polakova K. Antigenic glycopolypeptides HA1 and HA2 of influenza virus haemagglutinin. IV. Immunogenic properties of separated haemagglutinin glycopolypeptides. Acta Virol 1979; 23: 9-20.
79. Kostolansky F, Mucha V, Slovakova R, Vareckova E. Natural influenza A virus infection of mice elicits strong antibody response to HA2 glycopolypeptide. Acta Virol 2002; 46: 229-36.
80. Ekiert DC, Bhabha G, Elsliger MA, et al. Antibody recognition of a highly conserved influenza virus epitope. Science 2009; 324: 246-51.
81. Throsby M, van den Brink E, Jongeneelen M, et al. Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS One 2008; 3: e3942.
82. Okuno Y, Isegawa Y, Sasao F, Ueda S. A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains. J Virol 1993; 67: 2552-8.
83. Smirnov YA, Lipatov AS, Gitelman AK, Claas EC, Osterhaus AD. Prevention and treatment of bronchopneumonia in mice caused by mouse-adapted variant of avian H5N2 influenza A virus using monoclonal antibody against conserved epitope in the HA stem region. Arch Virol 2000; 145: 1733-41.
84. Smirnov YA, Lipatov AS, Gitelman AK, et al. An epitope shared by the hemagglutinins of H1, H2, H5, and H6 subtypes of influenza A virus. Acta Virol 1999; 43: 237-44.
85. Oh HL, Akerstrom S, Shen S, et al. An antibody against a novel and conserved epitope in the hemagglutinin 1 subunit neutralizes numerous H5N1 influenza viruses. J Virol 2010; 84: 8275-86.
86. Du A, Daidoji T, Koma T, et al. Detection of circulating Asian H5N1 viruses by a newly established monoclonal antibody. Biochem Biophys Res Commun 2009; 378: 197-202.
87. Vareckova E, Mucha V, Kostolansky F, Gubareva LV, Klimov A. HA2-specific monoclonal antibodies as tools for differential recognition of influenza A virus antigenic subtypes. Virus Res 2008; 132: 181-6.
88. Wang TT, Tan GS, Hai R, et al. Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins. PLoS Pathog 2010; 6: e1000796.
89. Veljkovic V, Veljkovic N, Muller CP, et al. Characterization of conserved properties of hemagglutinin of H5N1 and human influenza viruses: possible consequences for therapy and infection control. BMC Struct Biol 2009; 9(21).
90. Su Y, Yang HY, Zhang BJ, Jia HL, Tien P. Analysis of a point mutation in H5N1 avian influenza virus hemagglutinin in relation to virus entry into live mammalian cells. Arch Virol 2008; 153: 2253-61.
91. Kubota-Koketsu R, Mizuta H, Oshita M, et al. Broad neutralizing human monoclonal antibodies against influenza virus from vaccinated healthy donors. Biochem Biophys Res Commun 2009; 387: 180-5.
92. Yamashita A, Kawashita N, Kubota-Koketsu R, et al. Highly conserved sequences for human neutralization epitope on hemagglutinin of influenza A viruses H3N2, H1N1 and H5N1: Implication for human monoclonal antibody recognition. Biochem Biophys Res Commun 2010; 393: 614-8.
93. Wang SF, Chen KH, Thitithanyanont A, et al. Generating and characterizing monoclonal and polyclonal antibodies against avian H5N1 hemagglutinin protein. Biochem Biophys Res Commun 2009; 382: 691-6.
94. Bianchi E, Liang X, Ingallinella P, et al. Universal influenza B vaccine based on the maturational cleavage site of the hemagglutinin precursor. J Virol 2005; 79: 7380-8.
95. Horvath A, Toth GK, Gogolak P, et al. A hemagglutinin-based multipeptide construct elicits enhanced protective immune response in mice against influenza A virus infection. Immunol Lett 1998; 60: 127-36.
96. Nobusawa E, Aoyama T, Kato H, Suzuki Y, Tateno Y, Nakajima K. Comparison of complete amino acid sequences and receptor-binding properties among 13 serotypes of hemagglutinins of influenza A viruses. Virology 1991; 182: 475-85.
97. Chun S, Li C, Van Domselaar G, et al. Universal antibodies and their applications to the quantitative determination of virtually all subtypes of the influenza A viral hemagglutinins. Vaccine 2008; 26: 6068-76.
98. Somvanshi P, Singh V, Seth PK. Prediction of epitopes in hemagglutinin and neuraminidase proteins of influenza A virus H5N1 strain: a clue for diagnostic and vaccine development. OMICS 2008; 12: 61-9.
99. Parida R, Shaila MS, Mukherjee S, Chandra NR, Nayak R. Computational analysis of proteome of H5N1 avian influenza virus to define T cell epitopes with vaccine potential. Vaccine 2007; 25: 7530-9.
100. Gupta SK, Srivastava M, Akhoon BA, et al. Identification of immunogenic consensus T-cell epitopes in globally distributed influenza-A H1N1 neuraminidase. Infect Genet Evol 2011; 11: 308-19.
101. Ghosh A, Nandy A, Nandy P. Computational analysis and determination of a highly conserved surface exposed segment in H5N1 avian flu and H1N1 swine flu neuraminidase. BMC Struct Biol 2010; 10(6).
102. Gravel C, Li C, Wang J, et al. Qualitative and quantitative analyses of virtually all subtypes of influenza A and B viral neuraminidases using antibodies targeting the universally conserved sequences. Vaccine 2010; 28: 5774-84.
103. Xiao-Ping K, Yong-Qiang L, Qing-Ge S, Hong L, Qing-Yu Z, Yin-Hui Y. Development of a Consensus Microarray Method for Identification of Some Highly Pathogenic Viruses. J Med Virol 2009; 81:1945-1950.
104. Mehlmann M, Dawson ED, Townsend MB, et al. Robust Sequence Selection Method Used To Develop the FluChip Diagnostic Microarray for Influenza Virus. J Clin Microbiol 2006; 44: 2857-2862.
105. Townsend MB, Dawson ED, Mehlmann M, et al. Experimental Evaluation of the FluChip Diagnostic Microarray for Influenza Virus Surveillance. J Clin Microbiol 2006; 44: 2863-2871.
106. Smagala JA, Dawson ED, Mehlmann M, Townsend MB, Kuchta RD, Rowlen KL. ConFind: a robust tool for conserved sequence identification. Bioinformatics 2005; 21: 4420-4422.
107. Bose ME, Littrell JC, Patzer AD, et al. The Influenza Primer Design Resource: a new tool for translating influenza sequence data into effective diagnostics. Influenza Other Respi Viruses 2008; 2: 23-31.
108. Smith DJ. Applications of bioinformatics and computational biology to influenza surveillance and vaccine strain selection. Vaccine 2003; 21: 1758-1761.
109. Lees WD, Moss DS, Shepherd AJ. A computational analysis of the antigenic properties of haemagglutinin in influenza A H3N2. Bioinformatics 2010; 26: 1403-1408.
110. Smith DJ, Lapedes AA, de Jong JC, et al. Mapping the antigenic and genetic evolution of influenza virus. Science 2004; 35: 371-376.
111. Cai Z, Zhang T, Wan XF. A Computational Framework for Influenza Antigenic Cartography. PLoS Comput Biol 2010; 6(10): e1000949.
112. Lapedes A, Farber R. The geometry of shape space: application to influenza. J Theor Biol 2001; 212: 51-69.
113. Burr T. Phylogenetic Trees in Bioinformatics. Curr Bioinform 2010; 5: 40-52.
114. Liao YC, Lee MS, Ko CY, Hsiung CA. Bioinformatics models for predicting antigenic variants of influenza A/H3N2 virus. Bioinformatics 2008; 24: 505-12.
115. Ahn I, Jeong BJ, Bae SE, Jung J, Son HS. Genomic Analysis of Influenza A Viruses, including Avian Flu (H5N1) Strains. Eur J Epidemiol 2006; 21: 511-519.
116. Ahn I, Son HS. Comparative study of the hemagglutinin and neuraminidase genes of influenza A virus H3N2, H9N2, and H5N1 subtypes using bioinformatics Techniques. Can J Microbiol 2007; 53: 830-839.
117. Ahn I, Son HS. Comparative Study of the Nucleotide Bias Between the Novel H1N1 and H5N1 Subtypes of Influenza A Viruses Using Bioinformatics Techniques. J Microbiol Biotechnol 2010; 20: 59-66.
118. Lee MS, Chen JS. Predicting antigenic variants of influenza A/H3N2 viruses. Emerg Infect Dis 2004; 10: 1385-90.
119. Rabadan R, Levine AJ, Krasnitz M. Non-random reassortment in human influenza A viruses. Influenza Other Resp Viruses 2008; 2: 9-22.
120. Nagarajan N, Kingsford C. GiRaF: robust, computational identification of influenza reassortments via graph mining. Nucleic Acids Res 2011; 39: e34.
121. Liao YC, Ko CY, Tsai MH, Lee MS, Hsiung CA, ATIVS: analytical tool for influenza virus surveillance, Nucleic Acids Res 2009; 37(Web Server issue): W643-6.
122. Wood JM, Dunleavy U, Newman RW, Riley AM, Robertson JS, Minor PD. The influence of the host cell on standardisation of influenza vaccine potency. Dev Biol Stand 1999; 98: 183-8.
123. Rott R, Becht H, Orlich M. The significance of influenza virus neuraminidase in immunity. J Gen Virol 1974; 22: 35-41.
124. Johansson BE, Grajower B, Kilbourne ED. Infection-permissive immunization with influenza virus neuraminidase prevents weight loss in infected mice. Vaccine 1993; 11: 1037-9.
125. Schulman JL, Khakpour M, Kilbourne ED. Protective effects of specific immunity to viral neuraminidase on influenza virus infection of mice. J Virol 1968; 2: 778-86.
126. Takahashi Y, Hasegawa H, Hara Y, et al. Protective immunity afforded by inactivated H5N1 (NIBRG-14) vaccine requires antibodies against both hemagglutinin and neuraminidase in mice. J Infect Dis 2009; 199: 1629-37.
127. Webster RG, Laver WG, Kilbourne ED. Reactions of antibodies with surface antigens of influenza virus. J Gen Virol 1968; 3: 315-26.
128. Sandbulte MR, Jimenez GS, Boon AC, Smith LR, Treanor JJ, Webby RJ. Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. PLoS Med 2007; 4: e59.
129. Sylte MJ, Suarez DL. Influenza neuraminidase as a vaccine antigen. Curr Top Microbiol Immunol 2009; 333: 227-41.
130. DiNapoli JM, Nayak B, Yang L, et al. Newcastle disease virus-vectored vaccines expressing the hemagglutinin or neuraminidase protein of H5N1 highly pathogenic avian influenza virus protect against virus challenge in monkeys. J Virol 2010; 84: 1489-503.
131. Ogra PL, Chow T, Beutner KR, et al. Clinical and immunologic evaluation of neuraminidase-specific influenza A virus vaccine in humans. J Infect Dis 1977; 135: 499-506.
132. Beutner KR, Chow T, Rubi E, Strussenberg J, Clement J, Ogra PL. Evaluation of a neuraminidase-specific influenza A virus vaccine in children: antibody responses and effects on two successive outbreaks of natural infection. J Infect Dis 1979; 140: 844-50.
133. Kilbourne ED, Couch RB, Kasel JA, et al. Purified influenza A virus N2 neuraminidase vaccine is immunogenic and non-toxic in humans. Vaccine 1995; 13: 1799-803.
134. Couch RB, Kasel JA, Gerin JL, Schulman JL, Kilbourne ED. Induction of partial immunity to influenza by a neuraminidase-specific vaccine. J Infect Dis 1974; 129: 411-20.
135. Murphy BR, Kasel JA, Chanock RM. Association of serum anti-neuraminidase antibody with resistance to influenza in man. N Engl J Med 1972; 286: 1329-32.
136. Cate TR, Rayford Y, Nino D, et al. A high dosage influenza vaccine induced significantly more neuraminidase antibody than standard vaccine among elderly subjects. Vaccine 2010; 28: 2076-9.
137. Harvey R, Wheeler JX, Wallis CL, Robertson JS, Engelhardt OG. Quantitation of haemagglutinin in H5N1 influenza viruses reveals low haemagglutinin content of vaccine virus NIBRG-14 (H5N1). Vaccine 2008; 26: 6550-4.
138. Li C, Jaentschke B, Song Y, et al. A simple slot blot for the detection of virtually all subtypes of the influenza A viral hemagglutinins using universal antibodies targeting the fusion peptide. Nat Protoc 2010; 5: 14-9.
139. Gravel C, Li C, Wang J, et al. Quantitative analyses of all influenza type a viral hemagglutinins and neuraminidases using universal antibodies in simple slot blot assays. http://www.jove.com/details.php?id=2784, doi: 10.3791/2784. J Vis Exp 2011; 50.
140. Zhou B, Zhong N, Guan Y. Treatment with convalescent plasma for influenza A (H5N1) infection. N Engl J Med 2007; 357: 1450-1.
141. Yeh KM, Chiueh TS, Siu LK, et al. Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital. J Antimicrob Chemother 2005; 56: 919-22.
142. Nestorowicz A, Tregear GW, Southwell CN, et al. Antibodies elicited by influenza virus hemagglutinin fail to bind to synthetic peptides representing putative antigenic sites. Mol Immunol 1985; 22: 145-54.
143. Schoofs PG, Geysen HM, Jackson DC, Brown LE, Tang XL, White DO. Epitopes of an influenza viral peptide recognized by antibody at single amino acid resolution. J Immunol 1988; 140: 611-6.
144. Jackson DC, Brown LE. A synthetic peptide of influenza virus hemagglutinin as a model antigen and immunogen. Pept Res 1991; 4: 114-24.
145. McSwiggen JA, Seth S. A potential treatment for pandemic influenza using siRNAs targeting conserved regions of influenza A. Expert Opin Biol Ther 2008; 8: 299-313.
146. Naito Y, Ui-Tei K, Nishikawa T, Takebe Y, Saigo K. SiVirus: web-based antiviral siRNA design software for highly divergent viral sequences. Nucleic Acids Res 2006; 34(Web Server issue): W448-50.
147. Sarker R, Bandyopadhyay S, Maulik U. An Overview of Computational Approaches for Prediction of miRNA Genes and their Targets. Curr Bioinform 2011; 6: 129-143.
148. Cullen BR. Viruses and microRNAs. Nat Genet 2006; 38: S25-S30.
149. Scaria V, Hariharan M, Maiti S, Pillai B, Brahmachari SK. Host-virus interaction: a new role for microRNAs. Retrovirology 2006; 3:68.
150. Li SC, Shiau CK, Lin WC. Vir-Mir db: prediction of viral microRNA candidate hairpins. Nucleic Acids Res 2007; 36(Database issue): D184-9.
151. Wang ST, Li C, Liu L. miRNA Microarray Technology in miRNA Profiling. Curr Bioinform 2009; 4: 141-148.
152. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435: 834-838.
153. Hsu PWC, Lin LZ, Hsu SD, Hsu JBK, Huang HD. ViTa: prediction of host microRNAs targets on viruses. Nucleic Acids Res 2007; 35(Database issue): D381-D385.
154. John B, Enright AJ, Aravin A, Tusch T, Sander C, Marks DS. Human MicroRNA targets. PLoS Biol 2004; 2: e363.
155. Lewis BP, Shih IH, Jones-Rhoades MW, Barte DP, Burge CB. Prediction of mammalian microRNA targets. Cell 2003; 115: 787-798.